Dosage individualization of warfarin using artificial neural networks

Molecular Diagnosis and Therapy

Volumn 18, Issue 3, 2014, Pages 371-379

  Saleh, Mohammad I ^a   Alzubiedi, Sameh ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; CARBAMAZEPINE; CYTOCHROME P450 2C9; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; PHENYTOIN; PROTEIN; PROTEIN VKORC1; PYRROLE; RIFAMPICIN; SULFONAMIDE; UNCLASSIFIED DRUG; WARFARIN;

ADOLESCENT; ADULT; AGED; ALGORITHM; ARTICLE; ARTIFICIAL NEURAL NETWORK; BODY HEIGHT; BODY WEIGHT; CHILD; CLINICAL STUDY; CONGESTIVE HEART FAILURE; DEMOGRAPHY; DIABETES MELLITUS; ETHNICITY; FEMALE; GENETIC DATABASE; GENOTYPE; HUMAN; INDIVIDUALIZATION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RACE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; COHORT ANALYSIS; DOSE CALCULATION; MIDDLE AGED; REGRESSION ANALYSIS; VALIDATION STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CHILD; COHORT STUDIES; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); REGRESSION ANALYSIS; VALIDATION STUDIES AS TOPIC; WARFARIN; YOUNG ADULT;

EID: 84902382974     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-014-0090-7     Document Type: Article

References (50)

1. Cini M, Legnani C, Cosmi B, Guazzaloca G, Valdre L, Frascaro M, et al. A new warfarin dosing algorithm including VKORC1 3730 G>A polymorphism: comparison with results obtained by other published algorithms. Eur J Clin Pharmacol. 2012;68(8):1167-74.
2. Tan GM, Wu E, Lam YY, Yan BP. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics. 2010;11(3):439-48.
3. Lazo-Langner A, Kovacs MJ. Predicting warfarin dose. Curr Opin Pulm Med. 2010;16(5):426-31.
4. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002-12.
5. Verheugt FW. Anticoagulant management in the cardiovascular setting. Fundam Clin Pharmacol. 2012;26(1):11-5.
6. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329-33. (Pubitemid 41510803)
7. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116(22):2563-70. (Pubitemid 350179221)
8. Carlquist JF, Horne BD, Muhlestein JB, Lappe DL, Whiting BM, Kolek MJ, et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis. 2006;22(3):191-7. (Pubitemid 44857780)
9. International Warfarin Pharmacogenetics C, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753-64.
10. Graupe D, ebrary Inc. Principles of artificial neural networks. Advanced series on circuits and systems vol 6. 2nd ed. Singapore; Hackensack, N.J.: World Scientific,; 2007. p. xv, 303 p.
11. Agatonovic-Kustrin S, Beresford R. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. J Pharma Biomed Anal. 2000;22(5):717-27. (Pubitemid 30193303)
12. Yamamura S, Kawada K, Takehira R, Nishizawa K, Katayama S, Hirano M, et al. Artificial neural network modeling to predict the plasma concentration of aminoglycosides in burn patients. Biomed Pharmacother Biomedecine & pharmacotherapie. 2004;58(4):239-44.
13. Gaweda AE, Jacobs AA, Brier ME, Zurada JM. Pharmacodynamic population analysis in chronic renal failure using artificial neural networks-a comparative study. Neural Netw. 2003;16(5-6):841-5. (Pubitemid 36794360)
14. Kim YS, Sohn SY, Kim DK, Kim D, Paik YH, Shim HS. Screening test data analysis for liver disease prediction model using growth curve. Biomed Pharmacoth Biomedecine & pharmacotherapie. 2003;57(10):482-8.
15. Camps-Valls G, Porta-Oltra B, Soria-Olivas E, Martin-Guerrero JD, Serrano-Lopez AJ, Perez-Ruixo JJ, et al. Prediction of cyclosporine dosage in patients after kidney transplantation using neural networks. IEEE Trans Bio Med Eng. 2003;50(4):442-8. (Pubitemid 36438221)
16. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285-93. (Pubitemid 40740552)
17. Roper N, Storer B, Bona R, Fang M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn JMD. 2010;12(3):283-91.
18. Solomon I, Maharshak N, Chechik G, Leibovici L, Lubetsky A, Halkin H, et al. Applying an artificial neural network to warfarin maintenance dose prediction. Israel Med Assoc J IMAJ. 2004;6(12):732-5. (Pubitemid 39646685)
19. Narayanan MN, Lucas SB. A genetic algorithm to improve a neural network to predict a patient's response to warfarin. Methods Inf Med. 1993;32(1):55-8. (Pubitemid 23117617)
20. Hu YH, Wu F, Lo CL, Tai CT. Predicting warfarin dosage from clinical data: a supervised learning approach. Artif Intell Med. 2012;56(1):27-34.
21. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326-31.
22. Isma'eel HA, Sakr GE, Habib RH, Almedawar MM, Zgheib NK, Elhajj IH. Improved accuracy of anticoagulant dose prediction using a pharmacogenetic and artificial neural network-based method. Eur J Clin Pharmacol. 2013.
23. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1 Suppl):8S-21S. (Pubitemid 32154192)
24. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095-106. (Pubitemid 40720733)
25. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med. 1992;116(11):901-4. (Pubitemid 23034781)
26. Mungall D, White R. Aging and warfarin therapy. Ann Intern Med. 1992;117(10):878-9.
27. Kirking DM, Cohen IA, Shue ME, Hutchison TA. Relationship of age, weight and body surface area to warfarin maintenance dose requirements. J Clin Hosp Pharm. 1985;10(1):101-5. (Pubitemid 15103377)
28. Moreau C, Bajolle F, Siguret V, Lasne D, Golmard JL, Elie C, et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood. 2012;119(3):861-7.
29. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther. 2004;75(3):204-12. (Pubitemid 38314870)
30. Shen AY, Chen W, Yao JF, Brar SS, Wang X, Go AS. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. CNS Drugs. 2008;22(10):815-25.
31. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67-74. (Pubitemid 26425815)
32. Wallin R, Wajih N, Hutson SM. VKORC1: a warfarin-sensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors. Vitam Horm. 2008;78:227-46.
33. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther. 2008;84(5):581-8.
34. Baillargeon J, Holmes HM, Lin YL, Raji MA, Sharma G, Kuo YF. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med. 2012;125(2):183-9.
35. Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy. 1997;17(5):917-28. (Pubitemid 27415096)
36. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283-93.
37. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294-303.
38. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414-7.
39. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomarkers Med. 2011;5(6):795-806.
40. Lurie Y, Loebstein R, Kurnik D, Almog S, Halkin H. Warfarin and vitamin K intake in the era of pharmacogenetics. Br J Clin Pharmacol. 2010;70(2):164-70.
41. Chen LY, Eriksson N, Gwilliam R, Bentley D, Deloukas P, Wadelius M. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood. 2005;106(10):3673-4. (Pubitemid 41609210)
42. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gammaglutamyl carboxylase) gene variants with warfarin sensitivity. Blood. 2004;103(7):2630-5. (Pubitemid 38393017)
43. Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J. 2008;8(1):53-60.
44. Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics. 2008;9(5):511-26. (Pubitemid 351803913)
45. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MTM, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010;115(18):3827-34.
46. Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013;382(9894):790-6.
47. Routledge PA, Davies DM, Bell SM, Cavanagh JS, Rawlins MD. Predicting patients' warfarin requirements. Lancet. 1977;2(8043):854-5. (Pubitemid 8199533)
48. Sawyer WT, Poe TE, Canaday BR, Weiner JS, Williams DM, Webb CE, et al. Multicenter evaluation of six methods for predicting warfarin maintenance-dose requirements from initial response. Clin Pharm. 1985;4(4):440-6. (Pubitemid 15234458)
49. Lazo-Langner A, Monkman K, Kovacs MJ. Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram. J Thromb Haemost. 2009;7(8):1276-83.
50. Le Gal G, Carrier M, Tierney S, Majeed H, Rodger M, Wells PS. Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping? J Thromb Haemost. 2010;8(1):90-4.